Citi raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $84 and keeps a Buy rating on the shares. The firm updated models in medical technology following the Q1 reports. The good news is that underlying sector fundamentals appear intact, including volumes, pricing, and capex, the analyst tells investors in a research note. Citi named Edwards Lifesciences a Top Pick designation while removing Insulet (PODD). The firm says Edwards has several product and clinical milestones over the next 12-18 months.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $83 from $80 at Piper Sandler
- Edwards Lifesciences Expands Employee Stock Purchase Plans
- Balanced Outlook on Edwards Lifesciences: Navigating FDA Approval and Capacity Constraints
- Cadence, Apple, Edwards, Mondelez, American Water: Trending by Analysts
- Edwards Lifesciences Reports Robust Q1 2025 Growth